143 related articles for article (PubMed ID: 17854831)
41. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
[TBL] [Abstract][Full Text] [Related]
42. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
Sanz C; Andrieu S; Sinclair A; Hanaire H; Vellas B;
Neurology; 2009 Oct; 73(17):1359-66. PubMed ID: 19858457
[TBL] [Abstract][Full Text] [Related]
43. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
44. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
45. Rate of progression in Alzheimer's disease correlates with coated-platelet levels--a longitudinal study.
Prodan CI; Ross ED; Vincent AS; Dale GL
Transl Res; 2008 Sep; 152(3):99-102. PubMed ID: 18774538
[TBL] [Abstract][Full Text] [Related]
46. Effects of Alzheimer's disease and mild cognitive impairment on driving ability: a controlled clinical study by simulated driving test.
Frittelli C; Borghetti D; Iudice G; Bonanni E; Maestri M; Tognoni G; Pasquali L; Iudice A
Int J Geriatr Psychiatry; 2009 Mar; 24(3):232-8. PubMed ID: 18615781
[TBL] [Abstract][Full Text] [Related]
47. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Lundh T; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
[TBL] [Abstract][Full Text] [Related]
48. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
[TBL] [Abstract][Full Text] [Related]
49. Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T; Shoji M
Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
[TBL] [Abstract][Full Text] [Related]
50. [Discriminatory validity and association of the mini-mental test (MMSE) and the memory alteration test (M@T) with a neuropsychological battery in patients with amnestic mild cognitive impairment and Alzheimer's disease].
Rami L; Bosch B; Valls-Pedret C; Caprile C; Sánchez-Valle Díaz R; Molinuevo JL
Rev Neurol; 2009 Aug 16-31; 49(4):169-74. PubMed ID: 19621317
[TBL] [Abstract][Full Text] [Related]
51. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
52. The Severe Cognitive Impairment Rating Scale--an instrument for the assessment of cognition in moderate to severe dementia patients.
Choe JY; Youn JC; Park JH; Park IS; Jeong JW; Lee WH; Lee SB; Park YS; Jhoo JH; Lee DY; Kim KW
Dement Geriatr Cogn Disord; 2008; 25(4):321-8. PubMed ID: 18319591
[TBL] [Abstract][Full Text] [Related]
53. Potential biomarkers for dementia in Trinidad and Tobago.
Davis GK; Baboolal NS; Seales D; Ramchandani J; McKell S; McRae A
Neurosci Lett; 2007 Aug; 424(1):27-30. PubMed ID: 17703882
[TBL] [Abstract][Full Text] [Related]
54. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease.
Abe T; Tohgi H; Isobe C; Murata T; Sato C
J Neurosci Res; 2002 Nov; 70(3):447-50. PubMed ID: 12391605
[TBL] [Abstract][Full Text] [Related]
55. Serum nitrosative stress levels are increased in Alzheimer disease but not in vascular dementia.
Dildar K; Sinem F; Gökhan E; Orhan Y; Filiz M
Alzheimer Dis Assoc Disord; 2010; 24(2):194-7. PubMed ID: 20505437
[TBL] [Abstract][Full Text] [Related]
56. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease.
Lawlor BA; Bierer LM; Ryan TM; Schmeidler J; Knott PJ; Williams LL; Mohs RC; Davis KL
Biol Psychiatry; 1995 Aug; 38(3):185-8. PubMed ID: 7578662
[TBL] [Abstract][Full Text] [Related]
57. Recovery of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG) plasma concentrations during remission in patients suffering from atopic dermatitis.
Kasperska-Zajac A
Platelets; 2010; 21(7):522-4. PubMed ID: 20670105
[TBL] [Abstract][Full Text] [Related]
58. Glutamate uptake is decreased in platelets from Alzheimer's disease patients.
Ferrarese C; Begni B; Canevari C; Zoia C; Piolti R; Frigo M; Appollonio I; Frattola L
Ann Neurol; 2000 May; 47(5):641-3. PubMed ID: 10805335
[TBL] [Abstract][Full Text] [Related]
59. Increased myeloperoxidase plasma levels in patients with Alzheimer's disease.
Tzikas S; Schlak D; Sopova K; Gatsiou A; Stakos D; Stamatelopoulos K; Stellos K; Laske C
J Alzheimers Dis; 2014; 39(3):557-64. PubMed ID: 24217274
[TBL] [Abstract][Full Text] [Related]
60. Global intellectual deterioration in Alzheimer's disease and a reverse model of intellectual development: an applicability of the Binet scale.
Shimada M; Meguro K; Inagaki H; Ishizaki J; Yamadori A
Psychiatry Clin Neurosci; 2001 Dec; 55(6):559-63. PubMed ID: 11737787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
